- Home
- CRML vs PCRX Comparison
CRML vs PCRX Comparison
Compare CRML & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- PCRX
- Stock Information
- Founded
- CRML N/A
- PCRX 2006
- Country
- CRML United States
- PCRX United States
- Employees
- CRML N/A
- PCRX N/A
- Industry
- CRML
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- PCRX Health Care
- Exchange
- CRML NYSE
- PCRX Nasdaq
- Market Cap
- CRML 604.3M
- PCRX 604.7M
- IPO Year
- CRML N/A
- PCRX 2011
- Fundamental
- Price
- CRML $8.60
- PCRX $22.36
- Analyst Decision
- CRML
- PCRX Buy
- Analyst Count
- CRML 0
- PCRX 10
- Target Price
- CRML N/A
- PCRX $27.60
- AVG Volume (30 Days)
- CRML 74.1K
- PCRX 810.1K
- Earning Date
- CRML 02-01-2025
- PCRX 02-27-2025
- Dividend Yield
- CRML N/A
- PCRX N/A
- EPS Growth
- CRML N/A
- PCRX N/A
- EPS
- CRML N/A
- PCRX N/A
- Revenue
- CRML $117,660.00
- PCRX $694,957,000.00
- Revenue This Year
- CRML N/A
- PCRX $4.83
- Revenue Next Year
- CRML N/A
- PCRX $2.16
- P/E Ratio
- CRML N/A
- PCRX N/A
- Revenue Growth
- CRML 5.79
- PCRX 4.40
- 52 Week Low
- CRML $5.32
- PCRX $11.16
- 52 Week High
- CRML $22.50
- PCRX $34.01
- Technical
- Relative Strength Index (RSI)
- CRML 60.58
- PCRX 70.92
- Support Level
- CRML $7.29
- PCRX $18.18
- Resistance Level
- CRML $9.89
- PCRX $22.36
- Average True Range (ATR)
- CRML 0.76
- PCRX 1.13
- MACD
- CRML 0.12
- PCRX 0.30
- Stochastic Oscillator
- CRML 44.25
- PCRX 93.11
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.